PURPOSE To describe the outcomes of intravitreal injections of bevacizumab for choroidal neovascularization (CNV) associated with choroidal osteoma. METHODS Retrospective consecutive case series. Three eyes of three patients were studied. All patients were treated with intravitreal injections of bevacizumab for CNV associated with choroidal osteoma. Best-corrected visual acuity, central fovea...

Editor, A nti-VEGF agents, primarily bevacizumab, are emerging as a successful therapy for retinopathy of prematurity (ROP), particularly in aggressive posterior disease (Spandau et al. 2013). Concerns exist however regarding dosage, timing, duration of follow-up and long-term visual function. We conducted a prospective case– control study in 14 infants with symmetrical zone 1 or posterior zone...

OBJECTIVE To assess the effectiveness of intravitreal injection of Bevacizumab in the treatment of diabetic macular edema. METHODS This case series was conducted at Department of Ophthalmology, Jinnah Post Graduate Medical Centre (JPMC), Karachi. The duration of study was six months from May 26, 2011 to November 25, 2011. The study group comprised of 54 patients of the Diabetic Macular Edema ...

PURPOSE To report the effect of an intravitreal injection of 1.25 mg (0.05 ml) of bevacizumab (IVB) as symptomatic treatment for neovascular glaucoma. PATIENTS AND METHOD This prospective study included 13 eyes of 12 patients presenting neovascular glaucoma, in two cases secondary to ischemic central retinal vein occlusion and, in ten cases, to proliferative diabetic retinopathy. Each patient...

OBJECTIVES To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). MATERIALS AND METHODS Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus exami...

OBJECTIVES To report the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor and the safety profile of multiple doses of bevacizumab from the same vial reused for multiple patients. DESIGN Case series. SETTING A private hospital in Hong Kong. PATIENTS A systematic retrospective review of consecutive intravitreal anti-vascular endothelial gr...

BACKGROUND Cystoid Macular Edema (CME) is one of the most common and sight threatening complications of uveitis. Intravitreal injection of corticosteroids and Anti-VEGF are two routine options for treatment. OBJECTIVE To compare the effects of intravitreal injections of Bevacizumab and Triamcinolone Acetonide for the treatment of persistent macular edema in non-infectious uveitis. METHODS I...

Almony A, Mansouri A, Shah GK & Blinder KJ (2011): Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Can J Ophthalmol 46: 182–185. Gasperini JL, Fawzi AA, Khondkaryan A et al. (2012): Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96: 14–20. Gregori NZ, Feuer W & Rosenfeld PJ (2010): Nove...

Cystoid macular edema (CME) is a relatively common painless condition usually accompanied by blurred vision. The prevalence of CME varied from 5% to 47% depending on cause of pathology. There are several treatments available for ME including intravitreal use of bevacizumab that has been used in different doses in few studies. However, there is still scarcity of data available on the use of beva...

The aim of this study is to report clinical course of choroidal neovascularization secondary to angioid streaks (AS) in two patients who underwent intravitreal bevacizumab therapy. Fundus examination, fluorescein angiography (FA) and optical coherence tomography (OCT) revealed the diagnosis of subfoveal classic choroidal neovascularization (CNV) in the right eye in patient 1 and in the left eye...